Advanced materials (Deerfield Beach, Fla.)

Powerful Liver-Targeting mRNA Nanoparticles Delivered by ApoE Without Using the Usual LDL Receptor

Updated

Abstract

Therapeutic levels of OTC protein expression are achieved with minimal toxicity in preclinical models using optimized mRNA-LNP formulations.

  • Lipid nanoparticle formulations influence how therapeutics are distributed in the body and taken up by cells.
  • A novel helper lipid, 1,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE), enhances liver-specific delivery by modulating lipid structure and apolipoprotein E binding.
  • A new ionizable lipid with an N-(2-Hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) (HEPBS) core allows for cellular uptake independent of the low-density lipoprotein receptor pathway.
  • The optimized formulations show robust dose responsiveness and sustained therapeutic expression.
  • Minimal toxicity is indicated by stable liver function markers and cytokine levels.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors declare no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free